Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 7/20 | 0.47 |
| ▸ | JUN | P05412 | 4/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 4/20 | 0.47 |
| ▸ | RELA | Q04206 | 4/20 | 0.47 |
| ▸ | LCK | P06239 | 8/20 | 0.46 |
| ▸ | XPO1 | O14980 | 3/20 | 0.40 |
| ▸ | ATF1 | P18846 | 4/20 | 0.39 |
| ▸ | ATR | Q13535 | 1/20 | 0.37 |
| ▸ | STK17B | O94768 | 1/20 | 0.37 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20558363 | 0.79 | LCK (0.47) | LCKXPO1STK17BSTK17AMEN1 | |
| SCHEMBL22145720 | 0.76 | NFKB1 (0.54) | NFKB1JUNNFKB2RELAXPO1 | |
| SCHEMBL2949398 | 0.73 | RXFP1 (0.51) | NFKB1JUNNFKB2RELAXPO1 | |
| SCHEMBL22145357 | 0.72 | NFKB1 (0.45) | NFKB1JUNNFKB2RELAXPO1 | |
| SCHEMBL27924029 | 0.71 | GAA (0.49) | ATRSTK17BSTK17AMEN1NPC1 | |
| SCHEMBL28558352 | 0.71 | NFKB1 (0.46) | NFKB1JUNNFKB2RELAXPO1 | |
| SCHEMBL30421442 | 0.71 | NFKB1 (0.46) | NFKB1JUNNFKB2RELAXPO1 | |
| SCHEMBL20558428 | 0.69 | NFKB1 (0.65) | NFKB1JUNNFKB2RELAXPO1 | |
| SCHEMBL19282905 | 0.69 | NFKB1 (0.43) | NFKB1JUNNFKB2RELAXPO1 | |
| SCHEMBL24951632 | 0.68 | RAB9A (0.52) | NFKB1JUNNFKB2RELAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11084824-B2 | Pyrazolopyrimidine derivatives, preparation method thereof, and pharmaceutical composition for use in preventing or treating cancer, autoimmune disease and brain disease containing the same as an active ingredient | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2021-08-10 | — | — | US | disclosed |
| US-20200199129-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR USE IN PREVENTING OR TREATING CANCER, AUTOIMMUNE DISEASE AND BRAIN DISEASE CONTAINING THE SAME AS AN ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2020-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11084824-B2 | Pyrazolopyrimidine derivatives, preparation method thereof, and pharmaceutical composition for use in preventing or treating cancer, autoimmune disease and brain disease containing the same as an active ingredient | BTK, SYK, LCK | NFKB1 1198/4885JUN 2847/4885NFKB2 2526/4885 |
| US-20200199129-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR USE IN PREVENTING OR TREATING CANCER, AUTOIMMUNE DISEASE AND BRAIN DISEASE CONTAINING THE SAME AS AN ACTIVE INGREDIENT | BTK, SYK, LCK | NFKB1 1198/4885JUN 2847/4885NFKB2 2526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.